ISCIENCE 润色咨询

iScience

出版年份：暂无数据 年文章数：3724 投稿命中率： 开通期刊会员，数据随心看

出版周期：M 自引率：暂无数据 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2192191, encodeId=ebf521921918e, content=偏重的研究方向：分子生物学<br>经验分享：有人with editor已经2周了吗？等着毕业焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 06:55:43 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2191929, encodeId=07d92191929f9, content=all reviews complete两周了，没反应，什么情况，大家都多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5faa5643859, createdName=ms3000001833238695, createdTime=Thu Mar 07 20:06:22 CST 2024, time=2024-03-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191538, encodeId=836b2191538c8, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df435497459, createdName=ms2000001970188134, createdTime=Wed Mar 06 16:43:13 CST 2024, time=2024-03-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2190727, encodeId=70432190e2715, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：仿生学;生物机械学<br>经验分享：有较大难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76199196116, createdName=ms9000001484335827, createdTime=Sun Mar 03 11:25:54 CST 2024, time=2024-03-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;药物;神经内科<br>经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症生物学;肿瘤<br>经验分享：投稿时间节点： 文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE， 审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2133083, encodeId=ecf621330836f, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：cell reports 转投Iscience，内部推荐后送审很快，一审20来天，给两个月的修改时间，二审速度就很快了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8546511012, createdName=ms4000000330780966, createdTime=Sat May 13 11:38:10 CST 2023, time=2023-05-13, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119444, encodeId=77ce211944461, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：CR转投，第二天送审 但是一审三个多月还没收到消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f5157134, createdName=146ab31fm78暂无昵称, createdTime=Wed Mar 15 01:06:17 CST 2023, time=2023-03-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163953, encodeId=fc1921639539b, content=请问大家，编辑有让上传WB的整张膜的原始数据吗？如果不能提供整张膜，只有裁剪后的膜的原始数据，应该怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3385731305, createdName=ms3000001607723978, createdTime=Fri Oct 20 14:01:33 CST 2023, time=2023-10-20, status=1, ipAttribution=上海)]
    2024-03-09 ms3000000526945160 来自湖北省

    偏重的研究方向：分子生物学
    经验分享：有人with editor已经2周了吗？等着毕业焦虑

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2192191, encodeId=ebf521921918e, content=偏重的研究方向：分子生物学<br>经验分享：有人with editor已经2周了吗？等着毕业焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 06:55:43 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2191929, encodeId=07d92191929f9, content=all reviews complete两周了，没反应，什么情况，大家都多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5faa5643859, createdName=ms3000001833238695, createdTime=Thu Mar 07 20:06:22 CST 2024, time=2024-03-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191538, encodeId=836b2191538c8, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df435497459, createdName=ms2000001970188134, createdTime=Wed Mar 06 16:43:13 CST 2024, time=2024-03-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2190727, encodeId=70432190e2715, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：仿生学;生物机械学<br>经验分享：有较大难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76199196116, createdName=ms9000001484335827, createdTime=Sun Mar 03 11:25:54 CST 2024, time=2024-03-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;药物;神经内科<br>经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症生物学;肿瘤<br>经验分享：投稿时间节点： 文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE， 审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2133083, encodeId=ecf621330836f, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：cell reports 转投Iscience，内部推荐后送审很快，一审20来天，给两个月的修改时间，二审速度就很快了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8546511012, createdName=ms4000000330780966, createdTime=Sat May 13 11:38:10 CST 2023, time=2023-05-13, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119444, encodeId=77ce211944461, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：CR转投，第二天送审 但是一审三个多月还没收到消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f5157134, createdName=146ab31fm78暂无昵称, createdTime=Wed Mar 15 01:06:17 CST 2023, time=2023-03-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163953, encodeId=fc1921639539b, content=请问大家，编辑有让上传WB的整张膜的原始数据吗？如果不能提供整张膜，只有裁剪后的膜的原始数据，应该怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3385731305, createdName=ms3000001607723978, createdTime=Fri Oct 20 14:01:33 CST 2023, time=2023-10-20, status=1, ipAttribution=上海)]
    2024-03-07 ms3000001833238695 来自广东省

    all reviews complete两周了，没反应，什么情况，大家都多久

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2192191, encodeId=ebf521921918e, content=偏重的研究方向：分子生物学<br>经验分享：有人with editor已经2周了吗？等着毕业焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 06:55:43 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2191929, encodeId=07d92191929f9, content=all reviews complete两周了，没反应，什么情况，大家都多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5faa5643859, createdName=ms3000001833238695, createdTime=Thu Mar 07 20:06:22 CST 2024, time=2024-03-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191538, encodeId=836b2191538c8, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df435497459, createdName=ms2000001970188134, createdTime=Wed Mar 06 16:43:13 CST 2024, time=2024-03-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2190727, encodeId=70432190e2715, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：仿生学;生物机械学<br>经验分享：有较大难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76199196116, createdName=ms9000001484335827, createdTime=Sun Mar 03 11:25:54 CST 2024, time=2024-03-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;药物;神经内科<br>经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症生物学;肿瘤<br>经验分享：投稿时间节点： 文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE， 审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2133083, encodeId=ecf621330836f, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：cell reports 转投Iscience，内部推荐后送审很快，一审20来天，给两个月的修改时间，二审速度就很快了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8546511012, createdName=ms4000000330780966, createdTime=Sat May 13 11:38:10 CST 2023, time=2023-05-13, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119444, encodeId=77ce211944461, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：CR转投，第二天送审 但是一审三个多月还没收到消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f5157134, createdName=146ab31fm78暂无昵称, createdTime=Wed Mar 15 01:06:17 CST 2023, time=2023-03-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163953, encodeId=fc1921639539b, content=请问大家，编辑有让上传WB的整张膜的原始数据吗？如果不能提供整张膜，只有裁剪后的膜的原始数据，应该怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3385731305, createdName=ms3000001607723978, createdTime=Fri Oct 20 14:01:33 CST 2023, time=2023-10-20, status=1, ipAttribution=上海)]
    2024-03-06 ms2000001970188134 来自湖北省

    2

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2192191, encodeId=ebf521921918e, content=偏重的研究方向：分子生物学<br>经验分享：有人with editor已经2周了吗？等着毕业焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 06:55:43 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2191929, encodeId=07d92191929f9, content=all reviews complete两周了，没反应，什么情况，大家都多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5faa5643859, createdName=ms3000001833238695, createdTime=Thu Mar 07 20:06:22 CST 2024, time=2024-03-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191538, encodeId=836b2191538c8, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df435497459, createdName=ms2000001970188134, createdTime=Wed Mar 06 16:43:13 CST 2024, time=2024-03-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2190727, encodeId=70432190e2715, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：仿生学;生物机械学<br>经验分享：有较大难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76199196116, createdName=ms9000001484335827, createdTime=Sun Mar 03 11:25:54 CST 2024, time=2024-03-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;药物;神经内科<br>经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症生物学;肿瘤<br>经验分享：投稿时间节点： 文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE， 审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2133083, encodeId=ecf621330836f, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：cell reports 转投Iscience，内部推荐后送审很快，一审20来天，给两个月的修改时间，二审速度就很快了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8546511012, createdName=ms4000000330780966, createdTime=Sat May 13 11:38:10 CST 2023, time=2023-05-13, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119444, encodeId=77ce211944461, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：CR转投，第二天送审 但是一审三个多月还没收到消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f5157134, createdName=146ab31fm78暂无昵称, createdTime=Wed Mar 15 01:06:17 CST 2023, time=2023-03-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163953, encodeId=fc1921639539b, content=请问大家，编辑有让上传WB的整张膜的原始数据吗？如果不能提供整张膜，只有裁剪后的膜的原始数据，应该怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3385731305, createdName=ms3000001607723978, createdTime=Fri Oct 20 14:01:33 CST 2023, time=2023-10-20, status=1, ipAttribution=上海)]
    2024-03-03 ms9000001484335827 来自广西

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：仿生学;生物机械学
    经验分享：有较大难度

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2192191, encodeId=ebf521921918e, content=偏重的研究方向：分子生物学<br>经验分享：有人with editor已经2周了吗？等着毕业焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 06:55:43 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2191929, encodeId=07d92191929f9, content=all reviews complete两周了，没反应，什么情况，大家都多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5faa5643859, createdName=ms3000001833238695, createdTime=Thu Mar 07 20:06:22 CST 2024, time=2024-03-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191538, encodeId=836b2191538c8, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df435497459, createdName=ms2000001970188134, createdTime=Wed Mar 06 16:43:13 CST 2024, time=2024-03-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2190727, encodeId=70432190e2715, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：仿生学;生物机械学<br>经验分享：有较大难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76199196116, createdName=ms9000001484335827, createdTime=Sun Mar 03 11:25:54 CST 2024, time=2024-03-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;药物;神经内科<br>经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症生物学;肿瘤<br>经验分享：投稿时间节点： 文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE， 审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2133083, encodeId=ecf621330836f, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：cell reports 转投Iscience，内部推荐后送审很快，一审20来天，给两个月的修改时间，二审速度就很快了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8546511012, createdName=ms4000000330780966, createdTime=Sat May 13 11:38:10 CST 2023, time=2023-05-13, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119444, encodeId=77ce211944461, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：CR转投，第二天送审 但是一审三个多月还没收到消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f5157134, createdName=146ab31fm78暂无昵称, createdTime=Wed Mar 15 01:06:17 CST 2023, time=2023-03-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163953, encodeId=fc1921639539b, content=请问大家，编辑有让上传WB的整张膜的原始数据吗？如果不能提供整张膜，只有裁剪后的膜的原始数据，应该怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3385731305, createdName=ms3000001607723978, createdTime=Fri Oct 20 14:01:33 CST 2023, time=2023-10-20, status=1, ipAttribution=上海)]
    2023-06-30 ms1000000536422640 来自江苏省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向：炎症;药物;神经内科
    经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up

    9

    展开9条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2192191, encodeId=ebf521921918e, content=偏重的研究方向：分子生物学<br>经验分享：有人with editor已经2周了吗？等着毕业焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 06:55:43 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2191929, encodeId=07d92191929f9, content=all reviews complete两周了，没反应，什么情况，大家都多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5faa5643859, createdName=ms3000001833238695, createdTime=Thu Mar 07 20:06:22 CST 2024, time=2024-03-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191538, encodeId=836b2191538c8, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df435497459, createdName=ms2000001970188134, createdTime=Wed Mar 06 16:43:13 CST 2024, time=2024-03-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2190727, encodeId=70432190e2715, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：仿生学;生物机械学<br>经验分享：有较大难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76199196116, createdName=ms9000001484335827, createdTime=Sun Mar 03 11:25:54 CST 2024, time=2024-03-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;药物;神经内科<br>经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症生物学;肿瘤<br>经验分享：投稿时间节点： 文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE， 审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2133083, encodeId=ecf621330836f, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：cell reports 转投Iscience，内部推荐后送审很快，一审20来天，给两个月的修改时间，二审速度就很快了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8546511012, createdName=ms4000000330780966, createdTime=Sat May 13 11:38:10 CST 2023, time=2023-05-13, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119444, encodeId=77ce211944461, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：CR转投，第二天送审 但是一审三个多月还没收到消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f5157134, createdName=146ab31fm78暂无昵称, createdTime=Wed Mar 15 01:06:17 CST 2023, time=2023-03-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163953, encodeId=fc1921639539b, content=请问大家，编辑有让上传WB的整张膜的原始数据吗？如果不能提供整张膜，只有裁剪后的膜的原始数据，应该怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3385731305, createdName=ms3000001607723978, createdTime=Fri Oct 20 14:01:33 CST 2023, time=2023-10-20, status=1, ipAttribution=上海)]
    2022-12-24 马疾香幽 来自上海

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：癌症生物学;肿瘤
    经验分享：投稿时间节点： 文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。

    32

    展开32条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2192191, encodeId=ebf521921918e, content=偏重的研究方向：分子生物学<br>经验分享：有人with editor已经2周了吗？等着毕业焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 06:55:43 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2191929, encodeId=07d92191929f9, content=all reviews complete两周了，没反应，什么情况，大家都多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5faa5643859, createdName=ms3000001833238695, createdTime=Thu Mar 07 20:06:22 CST 2024, time=2024-03-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191538, encodeId=836b2191538c8, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df435497459, createdName=ms2000001970188134, createdTime=Wed Mar 06 16:43:13 CST 2024, time=2024-03-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2190727, encodeId=70432190e2715, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：仿生学;生物机械学<br>经验分享：有较大难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76199196116, createdName=ms9000001484335827, createdTime=Sun Mar 03 11:25:54 CST 2024, time=2024-03-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;药物;神经内科<br>经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症生物学;肿瘤<br>经验分享：投稿时间节点： 文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE， 审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2133083, encodeId=ecf621330836f, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：cell reports 转投Iscience，内部推荐后送审很快，一审20来天，给两个月的修改时间，二审速度就很快了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8546511012, createdName=ms4000000330780966, createdTime=Sat May 13 11:38:10 CST 2023, time=2023-05-13, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119444, encodeId=77ce211944461, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：CR转投，第二天送审 但是一审三个多月还没收到消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f5157134, createdName=146ab31fm78暂无昵称, createdTime=Wed Mar 15 01:06:17 CST 2023, time=2023-03-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163953, encodeId=fc1921639539b, content=请问大家，编辑有让上传WB的整张膜的原始数据吗？如果不能提供整张膜，只有裁剪后的膜的原始数据，应该怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3385731305, createdName=ms3000001607723978, createdTime=Fri Oct 20 14:01:33 CST 2023, time=2023-10-20, status=1, ipAttribution=上海)]
    2023-02-10 1250d11bm60(暂无昵称) 来自浙江省

    的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE， 审稿人很专业。

    6

    展开6条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2192191, encodeId=ebf521921918e, content=偏重的研究方向：分子生物学<br>经验分享：有人with editor已经2周了吗？等着毕业焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 06:55:43 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2191929, encodeId=07d92191929f9, content=all reviews complete两周了，没反应，什么情况，大家都多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5faa5643859, createdName=ms3000001833238695, createdTime=Thu Mar 07 20:06:22 CST 2024, time=2024-03-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191538, encodeId=836b2191538c8, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df435497459, createdName=ms2000001970188134, createdTime=Wed Mar 06 16:43:13 CST 2024, time=2024-03-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2190727, encodeId=70432190e2715, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：仿生学;生物机械学<br>经验分享：有较大难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76199196116, createdName=ms9000001484335827, createdTime=Sun Mar 03 11:25:54 CST 2024, time=2024-03-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;药物;神经内科<br>经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症生物学;肿瘤<br>经验分享：投稿时间节点： 文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE， 审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2133083, encodeId=ecf621330836f, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：cell reports 转投Iscience，内部推荐后送审很快，一审20来天，给两个月的修改时间，二审速度就很快了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8546511012, createdName=ms4000000330780966, createdTime=Sat May 13 11:38:10 CST 2023, time=2023-05-13, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119444, encodeId=77ce211944461, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：CR转投，第二天送审 但是一审三个多月还没收到消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f5157134, createdName=146ab31fm78暂无昵称, createdTime=Wed Mar 15 01:06:17 CST 2023, time=2023-03-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163953, encodeId=fc1921639539b, content=请问大家，编辑有让上传WB的整张膜的原始数据吗？如果不能提供整张膜，只有裁剪后的膜的原始数据，应该怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3385731305, createdName=ms3000001607723978, createdTime=Fri Oct 20 14:01:33 CST 2023, time=2023-10-20, status=1, ipAttribution=上海)]
    2023-05-13 ms4000000330780966 来自福建省

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享：cell reports 转投Iscience，内部推荐后送审很快，一审20来天，给两个月的修改时间，二审速度就很快了

    3

    展开3条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2192191, encodeId=ebf521921918e, content=偏重的研究方向：分子生物学<br>经验分享：有人with editor已经2周了吗？等着毕业焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 06:55:43 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2191929, encodeId=07d92191929f9, content=all reviews complete两周了，没反应，什么情况，大家都多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5faa5643859, createdName=ms3000001833238695, createdTime=Thu Mar 07 20:06:22 CST 2024, time=2024-03-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191538, encodeId=836b2191538c8, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df435497459, createdName=ms2000001970188134, createdTime=Wed Mar 06 16:43:13 CST 2024, time=2024-03-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2190727, encodeId=70432190e2715, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：仿生学;生物机械学<br>经验分享：有较大难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76199196116, createdName=ms9000001484335827, createdTime=Sun Mar 03 11:25:54 CST 2024, time=2024-03-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;药物;神经内科<br>经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症生物学;肿瘤<br>经验分享：投稿时间节点： 文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE， 审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2133083, encodeId=ecf621330836f, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：cell reports 转投Iscience，内部推荐后送审很快，一审20来天，给两个月的修改时间，二审速度就很快了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8546511012, createdName=ms4000000330780966, createdTime=Sat May 13 11:38:10 CST 2023, time=2023-05-13, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119444, encodeId=77ce211944461, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：CR转投，第二天送审 但是一审三个多月还没收到消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f5157134, createdName=146ab31fm78暂无昵称, createdTime=Wed Mar 15 01:06:17 CST 2023, time=2023-03-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163953, encodeId=fc1921639539b, content=请问大家，编辑有让上传WB的整张膜的原始数据吗？如果不能提供整张膜，只有裁剪后的膜的原始数据，应该怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3385731305, createdName=ms3000001607723978, createdTime=Fri Oct 20 14:01:33 CST 2023, time=2023-10-20, status=1, ipAttribution=上海)]
    2023-03-15 146ab31fm78暂无昵称 来自广东省

    审稿速度:6.0 | 投稿命中率:50.0
    经验分享：CR转投，第二天送审 但是一审三个多月还没收到消息

    3

    展开3条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2192191, encodeId=ebf521921918e, content=偏重的研究方向：分子生物学<br>经验分享：有人with editor已经2周了吗？等着毕业焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb45427735, createdName=ms3000000526945160, createdTime=Sat Mar 09 06:55:43 CST 2024, time=2024-03-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2191929, encodeId=07d92191929f9, content=all reviews complete两周了，没反应，什么情况，大家都多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5faa5643859, createdName=ms3000001833238695, createdTime=Thu Mar 07 20:06:22 CST 2024, time=2024-03-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191538, encodeId=836b2191538c8, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df435497459, createdName=ms2000001970188134, createdTime=Wed Mar 06 16:43:13 CST 2024, time=2024-03-06, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2190727, encodeId=70432190e2715, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：仿生学;生物机械学<br>经验分享：有较大难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76199196116, createdName=ms9000001484335827, createdTime=Sun Mar 03 11:25:54 CST 2024, time=2024-03-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2145619, encodeId=ffd9214561947, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：炎症;药物;神经内科<br>经验分享：2023.3.4建议转投到iscience，4.3号给了意见大修，5.16修回去，5.30号左右给了原则性接收。然后又返修了四次格式等一些小问题，6.28正式接收。感觉编辑非常严格，格式当时四次修的佛系了都。希望期刊越来越好，明年影响因子能up up up, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9778331502, createdName=ms1000000536422640, createdTime=Fri Jun 30 09:39:07 CST 2023, time=2023-06-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2107286, encodeId=f52e210e286f3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症生物学;肿瘤<br>经验分享：投稿时间节点： 文章终于accept in principle了，来分享一下目前为止的时间线，供参考： 2022.8.11 投稿到Cell press community review 2022.8.17 被建议转投至iScience，8.18同意转投。 2022.8.19 完成iScience的提交并得到编辑确认，大概过了1-2天左右under review 2022.9.12 得到审稿结果，major revision 2022.11.28 修回 2022.12.6 under review 2022.12.23 all reviews complete 2022.12.24 accepted in principle 感觉整体来说审稿速度还是挺快的，我自己补实验补了两个多月，有的实验不算太顺利，但是好在审稿人也没有为难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cac51677430, createdName=马疾香幽, createdTime=Sat Dec 24 15:28:01 CST 2022, time=2022-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2114023, encodeId=8c6f211402315, content=的确非常感谢IScience, 课题组5年两项重要成果得到该期刊的认可，连续发表，同时ISCIECE 推荐发表STAR Protocolsl (invited article) , 编辑非常NICE， 审稿人很专业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08ec2535111, createdName=1250d11bm60(暂无昵称), createdTime=Fri Feb 10 20:55:14 CST 2023, time=2023-02-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2133083, encodeId=ecf621330836f, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：cell reports 转投Iscience，内部推荐后送审很快，一审20来天，给两个月的修改时间，二审速度就很快了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8546511012, createdName=ms4000000330780966, createdTime=Sat May 13 11:38:10 CST 2023, time=2023-05-13, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119444, encodeId=77ce211944461, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：CR转投，第二天送审 但是一审三个多月还没收到消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f5157134, createdName=146ab31fm78暂无昵称, createdTime=Wed Mar 15 01:06:17 CST 2023, time=2023-03-15, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163953, encodeId=fc1921639539b, content=请问大家，编辑有让上传WB的整张膜的原始数据吗？如果不能提供整张膜，只有裁剪后的膜的原始数据，应该怎么办？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3385731305, createdName=ms3000001607723978, createdTime=Fri Oct 20 14:01:33 CST 2023, time=2023-10-20, status=1, ipAttribution=上海)]
    2023-10-20 ms3000001607723978 来自上海

    请问大家，编辑有让上传WB的整张膜的原始数据吗？如果不能提供整张膜，只有裁剪后的膜的原始数据，应该怎么办？

    3

    展开3条回复
共260条页码: 2/26页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分